Plasma Levels of Decorin Increased in Patients during the Progression of Breast Cancer.

Abstract

Decorin (DCN), an extracellular matrix proteoglycan found in tumor surrounding tissues, is a natural inhibitor of tumor cell proliferation and invasion. We conducted a cross-sectional observation study to evaluate the association of the pathological stage with the levels of DCN in plasma or tumor surrounding tissue. Among 118 patients who underwent breast surgery, 35 were designated as carcinoma in situ (Stage 0), 39 were Stage I, and 44 were Stage II or III. The stromal expression of DCN was quantified using a semiquantitative digital image analysis after immunohistochemical staining. The concentration of DCN was evaluated with a specific ELISA. As we have previously shown, stromal DCN expression was attenuated in the patients with Stage I, whereas stromal and plasma DCN was elevated paradoxically in those with Stage II/III. The elevated plasma DCN is an independent predictive factor of Stage II/III by the multivariate logistic regression analysis. The plasma level of DCN was negatively correlated with stromal DCN expression only in patients with advanced disease (Stage II/III). The plasma level of DCN could become a useful biomarker for patients in the advanced stages. Extensive studies and further assessments are warranted for evaluating the prognostic significance and tumor characteristics to understand the clinical significances of stromal and systemic DCN.

• Authors: Tokuko Hosoya, Goshi Oda, Tsuyoshi Nakagawa, Iichiroh Onishi, Tadashi Hosoya, Megumi Ishiguro, Toshiaki Ishikawa, Hiroyuki Uetake
• Journal: Journal of clinical medicine (J Clin Med) Vol. 10 Issue 23 (Nov 26 2021) ISSN: 2077-0383 [Print] Switzerland
• PMID: 34884232 (Publication Type: Journal Article)